A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
← catalyst calendarNCT07223047 · readout in 786 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
252estimated
Sites
8
Countries
Canada, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-25 | actual | When the study began enrolling |
| Primary completion | 2028-10-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Malignancies
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
- Drug: BMS-986523
- Drug: Gemcitabine
- Drug: Nab-Paclitaxel
- Drug: Cetuximab
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 3 years
Number of participants with serious adverse events (SAEs)
measured Up to 3 years
Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria
measured Up to 3 years
Number of participants with AEs leading to discontinuation
measured Up to 3 years
Number of deaths
measured Up to 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed